Tri Locum Partners LP Has $35.83 Million Stake in argenx SE (NASDAQ:ARGX)

Tri Locum Partners LP lowered its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 58,258 shares of the company's stock after selling 4,216 shares during the quarter. argenx makes up about 7.4% of Tri Locum Partners LP's investment portfolio, making the stock its 3rd largest position. Tri Locum Partners LP owned approximately 0.10% of argenx worth $35,829,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. FMR LLC boosted its position in shares of argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in argenx during the third quarter worth about $88,339,000. Allspring Global Investments Holdings LLC grew its position in shares of argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after buying an additional 143,834 shares during the period. Marshall Wace LLP increased its stake in shares of argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after acquiring an additional 124,271 shares during the last quarter. Finally, Capital World Investors raised its position in shares of argenx by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after acquiring an additional 86,687 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Stock Up 1.6 %

Shares of ARGX traded up $10.03 during midday trading on Friday, hitting $649.93. The company's stock had a trading volume of 214,455 shares, compared to its average volume of 308,352. argenx SE has a one year low of $352.77 and a one year high of $678.21. The stock has a market capitalization of $39.68 billion, a price-to-earnings ratio of -740.18 and a beta of 0.60. The company's fifty day simple moving average is $597.82 and its two-hundred day simple moving average is $610.65.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, research analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ARGX. HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenx in a report on Tuesday, April 8th. Guggenheim raised their price objective on argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. JMP Securities increased their price target on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 14th. Piper Sandler boosted their price objective on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research report on Tuesday, January 7th. Finally, Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, argenx currently has an average rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.